Use of Sugammadex in a Patient with Amyotrophic Lateral Sclerosis

Kelsaka, Ebru; Karakaya, Deniz; Zengin, Eyüp Cağatayn

doi:10.1159/000343168

Cited by 24 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a patient with ALS reported by Kelsaka et al, clinical signs of inadequate recovery were observed despite a TOF ratio > 0.90. Two minutes after sugammadex 2 mg/kg was administered, the patient recovered clinically and was extubated uneventfully [58] (Table 5). A similar discrepancy between TOF ratio and clinical signs of muscle strength recovery was also reported by Chang et al [59,60].…”

Section: Neuropathies (Table 4)mentioning

confidence: 99%

Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports

2019

View full text Add to dashboard Cite

Background: Sugammadex is a modified gamma-cyclodextrin that acts by selectively encapsulating free aminosteroidal neuromuscular relaxants. Several case reports have been published on the use of sugammadex in patients with neuromuscular disorders that include neuromuscular junction diseases, myopathies, neuropathies, and motor neurone disorders. The primary aim of this review is to systematically review the evidence on the use of sugammadex in patients with this heterogeneous group of diseases and provide recommendations for clinical practice. Methods: A systematic electronic search of Medline, Embase and CINAHL databases was done until June 2019, to identify case reports describing the use of sugammadex in adult surgical patients with neuromuscular disorders. Results: Of the 578 records identified through database searches, 43 articles were finally included for the systematic review. Of these, 17 reports were on patients with myopathy, 15 reports on myasthenia gravis, 9 reports on motor neuron diseases and 2 reports on neuropathies. Conclusions: Majority of the articles reviewed report successful use of sugammadex to reverse steroidal muscle relaxants, especially rocuronium, in patients with neuromuscular diseases. However, with sugammadex, unpredictability in response and uncertainty regarding optimum dose still remain issues. Quantitative neuromuscular monitoring to ensure complete reversal and adequate postoperative monitoring is strongly recommended in these patients, despite the use of sugammadex.

show abstract

Section: Neuropathies (Table 4)mentioning

confidence: 99%

Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports

2019

View full text Add to dashboard Cite

show abstract

“…The challenge is caused by the extreme sensitivity of this population to NMBAs, which could lead to an overlong period of mechanical ventilation that could trigger respiratory and cardiovascular complications and also result in death [44]. Therefore, the combination rocuronium-sugammadex seems to be a safe and reliable option for patients with myasthenia gravis, multiple sclerosis, dermatomyositis, Sjogren's syndrome, Becker muscular dystrophy, Duchene muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, StrumpellLorrain disease, and amyotrophic lateral sclerosis [10,42,[45][46][47][48][49][50]. The rocuronium-sugammadex combination has been studied mainly in patients with myasthenia gravis.…”

Section: Advantages Of Sugammadex In Patients With Comorbidities Patimentioning

confidence: 99%

A Short Update on Sugammadex with a Special Focus on Economic Assessment of its Use in North America

Zaouter¹,

Mion²,

Palomba³

et al. 2017

J Anesth Clin Res

View full text Add to dashboard Cite

Sugammadex offers significant advantages over the current anticholinesterase reversal drugs. Sugammadex used has been approved for the United Stated and for Canada since December 2015 and February 2016, respectively. The present article aims to provide a straightforward and concise review of the most recent literature describing its clinical advantages in routine use. A thorough and cost-effective evaluation has been conducted specifically for North America to determine if its price justifies its inclusion into regular patients' care. The search examined the relevant literature from January 2013 to October 2016. The present narrative review describes how sugammadex could play a crucial role in the modern conduct of anesthesia. The particular emphasis on sugammadex cost-effective analysis performed in this article suggests that this new reversal agent should be considered for a wider use in North America.

show abstract

“…65 However, there are case reports of patients with ALS who underwent neuromuscular blockade and recovered quickly with the use of suggamadex. 66,67 Increased risk of malignant hyperthermia or rhabdomyolysis has not been reported in patients with ALS. 64 …”

Section: Surgical Risksmentioning

confidence: 99%

Palliative Care Issues in Amyotrophic Lateral Sclerosis

Karam

Paganoni

Joyce

et al. 2014

Am J Hosp Palliat Care

View full text Add to dashboard Cite

As palliative care physicians become increasingly involved in the care of patients with amyotrophic lateral sclerosis (ALS), they will be asked to provide guidance regarding the use of supplements, diet, exercise, and other common preventive medicine interventions. Moreover, palliative care physicians have a crucial role assisting patients with ALS in addressing health care decisions to maximize quality of life and cope with a rapidly disabling disease. It is therefore important for palliative care physicians to be familiar with commonly encountered palliative care issues in ALS. This article provides an evidenced-based review of palliative care options not usually addressed in national and international ALS guidelines.

show abstract

Use of Sugammadex in a Patient with Amyotrophic Lateral Sclerosis

Cited by 24 publications

References 6 publications

Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports

Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports

A Short Update on Sugammadex with a Special Focus on Economic Assessment of its Use in North America

Palliative Care Issues in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About